Sponsorship and Support: This webinar is sponsored by Primary Care Education Consortium, in collaboration with the Primary Care Metabolic Group. It is supported by an educational grant from Corcept Therapeutics.
Accreditation: In support of improving patient care, Primary Care Education Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the American Academy of PAs (AAPA) to provide continuing education for the healthcare team.
Credit Designation: This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. You may alternately request to receive ACCME, ACPE, ANCC, or AAPA certification. Other clinicians will receive a certificate of participation. The term of approval is August 1, 2025, to March 31, 2026.
Faculty Disclosure Information: Primary Care Education Consortium adheres to the conflict-of-interest policy of the ACCME, JA, and the AMA. It is the policy of PCEC to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. All individuals in a position to control the content in our programs are expected to disclose any relationships they may have with commercial companies whose products or services may be mentioned so that participants may evaluate the objectivity of the presentations. In addition, any discussion of off-label, experimental, or investigational use of drugs or devices will be disclosed by the faculty. Only those participants who have no conflict of interest or who agree to an identified mitigation process prior to their participation were involved in the CME activity.
Stephen Brunton, MD, discloses that he serves as a speaker of Eli Lilly, as a speaker and on the advisory board for Abbott and Boehringer Ingelheim, and on the advisory board for Novo Nordisk, Sanofi, and Biolinq. He holds stock options for Paracrine.
John Buse, MD, PhD, discloses that he is a consultant for Altimmune, Antag, Amgen, ApStem, Aqua Medical, AstraZeneca, Boehringer Ingelheim, CeQur, Corcept, Dexcom, Eli Lilly, Embecta, GentiBio, Insulet, MiniMed, Metsera, Novo Nordisk, Recordati, Tandem, Vertex, and Zealand; has stock or stock options in Glyscend, Mellitus Health, Metsera, Pendulum Therapeutics, Praetego, and Stability Health; and holds clinical trial contracts with Corcept Therapeutics, Dexcom and Novo Nordisk.
Jennifer Goldman, PharmD, discloses that she serves as a speaker for Lilly, Novo Nordisk, Amgen, Xeris and Cequr; and on the advisory board for Insulet.
Eden Miller, DO, discloses that she serves as a speaker for Bayer, Bi/Lilly, Novo Nordisk, Abbott, Insulet, Embecta, and Corcept; as a researcher for Abbott; and as an advisory board member for BI/Lilly, Abbott, Embecta, Insulet and Novo Nordisk.
Austin Ulrich, PharmD, medical writer, and Michael Hanak, MD, CME Reviewer, have no disclosures to report.
All relevant financial relationships have been mitigated.
To receive your certificate after watching the webinar, click HERE to complete the evaluation survey.
Thanks for watching our webinar!
Download PDF of slide deck.
For more information on the CATALYST TRIAL:
TREATMENT PHASE MANUSCRIPT:
DeFronzo RA, Fonseca V, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Buse JB, Christofides EA, Eilerman B, Findling JW, Handelsman Y, Kahn SE, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LA, Umpierrez G, Shambharkar S, Tudor IC, Schlafly TK, Einhorn D; CATALYST Investigators. Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care. 2025 Jun 23:dc251055. doi: 10.2337/dc25-1055. Epub ahead of print. PMID: 40550011.
PREVALENCE PHASE MANUSCRIPT:
Buse JB, Kahn SE, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Christofides EA, DeFronzo RA, Eilerman B, Findling JW, Fonseca V, Hamidi O, Handelsman Y, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LL, Umpierrez G, Tudor IC, Schlafly TK, Einhorn D; CATALYST Investigators. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care. 2025 Apr 18:dc242841. doi: 10.2337/dc24-2841. Epub ahead of print. PMID: 40249765.
STUDY DESIGN MANUSCRIPT:
DeFronzo RA, Auchus RJ, Bancos I, Blonde L, Busch RS, Buse JB, Findling JW, Fonseca VA, Frias JP, Hamidi O, Handelsman Y, Pratley RE, Rosenstock J, Tudor IC, Moraitis AG, Einhorn D. Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ Open. 2024 Jul 16;14(7):e081121. doi: 10.1136/bmjopen-2023-081121. PMID: 39013654; PMCID: PMC11253743.
c 